Effects of Carnosine Supplementation on Cognitive Outcomes in Prediabetes and Well-Controlled Type 2 Diabetes: A Randomised Placebo-Controlled Clinical Trial DOI Creative Commons
Rohit Hariharan, Aya Mousa, Kirthi Menon

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 630 - 630

Published: April 26, 2025

Background: Trends in global ageing underscore the rising burden of age-related cognitive decline and concomitant cardiometabolic diseases, including type 2 diabetes mellitus (T2DM). Carnosine, a naturally occurring dipeptide with anti-inflammatory, antioxidant anti-glycating properties, has shown promise animal models limited human studies for improving function, insulin resistance T2DM, but its therapeutic effects on cognition remain unclear. The aim this study is to assess carnosine function individuals prediabetes or well-controlled T2DM. Methods: This secondary analysis double-blind randomised controlled trial (RCT), whereby 49 adults early-stage T2DM were receive g identical placebo daily 14 weeks. At baseline follow-up, was assessed as outcome using Digit-Symbol Substitution Test, Stroop test, Trail Making Tests A & B, Cambridge Automated Neuropsychological Test Battery (CANTAB). Results: In total, 42 (23 males 19 females) completed trial. There no differences participant anthropometry functioning between groups at (all p > 0.1). After 14-week supplementation period, there change follow-up values any measures Stroop, Digit Symbol Sest, A/B CANTAB 0.05). Adjustments scores, diabetic status, level education, age interaction participants’ sex did not results. Conclusions: Carnosine improve study. While larger trials may provide further insights, alternative factors—such relatively young healthy profile our cohort—may have contributed lack observed effect. Future research should examine existing impairment those higher risk better define potential context.

Language: Английский

Effects of Carnosine Supplementation on Cognitive Outcomes in Prediabetes and Well-Controlled Type 2 Diabetes: A Randomised Placebo-Controlled Clinical Trial DOI Creative Commons
Rohit Hariharan, Aya Mousa, Kirthi Menon

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 630 - 630

Published: April 26, 2025

Background: Trends in global ageing underscore the rising burden of age-related cognitive decline and concomitant cardiometabolic diseases, including type 2 diabetes mellitus (T2DM). Carnosine, a naturally occurring dipeptide with anti-inflammatory, antioxidant anti-glycating properties, has shown promise animal models limited human studies for improving function, insulin resistance T2DM, but its therapeutic effects on cognition remain unclear. The aim this study is to assess carnosine function individuals prediabetes or well-controlled T2DM. Methods: This secondary analysis double-blind randomised controlled trial (RCT), whereby 49 adults early-stage T2DM were receive g identical placebo daily 14 weeks. At baseline follow-up, was assessed as outcome using Digit-Symbol Substitution Test, Stroop test, Trail Making Tests A & B, Cambridge Automated Neuropsychological Test Battery (CANTAB). Results: In total, 42 (23 males 19 females) completed trial. There no differences participant anthropometry functioning between groups at (all p > 0.1). After 14-week supplementation period, there change follow-up values any measures Stroop, Digit Symbol Sest, A/B CANTAB 0.05). Adjustments scores, diabetic status, level education, age interaction participants’ sex did not results. Conclusions: Carnosine improve study. While larger trials may provide further insights, alternative factors—such relatively young healthy profile our cohort—may have contributed lack observed effect. Future research should examine existing impairment those higher risk better define potential context.

Language: Английский

Citations

0